Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP David Sponsel sold 58,283 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the sale, the executive vice president now directly owns 502,311 shares of the company's stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
David Sponsel also recently made the following trade(s):
- On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total value of $2,380.00.
Alphatec Price Performance
Shares of Alphatec stock traded up $0.24 during trading on Tuesday, reaching $11.12. The company's stock had a trading volume of 2,321,717 shares, compared to its average volume of 2,052,927. The business has a 50 day moving average price of $9.49 and a 200-day moving average price of $8.00. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $17.34. The company has a market capitalization of $1.58 billion, a P/E ratio of -8.69 and a beta of 1.41. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.
Hedge Funds Weigh In On Alphatec
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in shares of Alphatec in the third quarter valued at $69,000. Net Worth Advisory Group acquired a new position in Alphatec during the third quarter worth about $76,000. Van ECK Associates Corp lifted its holdings in shares of Alphatec by 57.0% in the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company's stock valued at $99,000 after purchasing an additional 6,998 shares in the last quarter. Tempus Wealth Planning LLC acquired a new stake in shares of Alphatec in the third quarter valued at approximately $107,000. Finally, Atria Investments Inc increased its stake in shares of Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company's stock worth $109,000 after purchasing an additional 1,460 shares in the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have recently commented on ATEC shares. Barclays raised their price objective on shares of Alphatec from $19.00 to $20.00 and gave the company an "overweight" rating in a research note on Tuesday, November 19th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday. Finally, Needham & Company LLC increased their price objective on shares of Alphatec from $13.00 to $16.00 and gave the company a "buy" rating in a research report on Monday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.44.
Read Our Latest Stock Report on ATEC
About Alphatec
(
Get Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alphatec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.
While Alphatec currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
